×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABBV – abbvie inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABBV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/18
07:28 pm
abbv
AbbVie (ABBV) Stock Moves -0.29%: What You Should Know [Yahoo! Finance]
Low
Report
AbbVie (ABBV) Stock Moves -0.29%: What You Should Know [Yahoo! Finance]
3/18
01:18 pm
abbv
Factbox-Widely used drugs on US imports list from Europe [Yahoo! Finance]
Low
Report
Factbox-Widely used drugs on US imports list from Europe [Yahoo! Finance]
3/18
01:11 pm
abbv
Factbox-Widely used drugs on US imports list from Europe [Yahoo! Finance Canada]
Low
Report
Factbox-Widely used drugs on US imports list from Europe [Yahoo! Finance Canada]
3/17
10:46 am
abbv
Oncology Drugs Market Size to Surpass USD 530.39 Billion by 2032, Driven by Advancements in Targeted Therapies and Rising Cancer Incidence – SNS Insider [Yahoo! Finance]
Low
Report
Oncology Drugs Market Size to Surpass USD 530.39 Billion by 2032, Driven by Advancements in Targeted Therapies and Rising Cancer Incidence – SNS Insider [Yahoo! Finance]
3/17
08:45 am
abbv
PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment [Yahoo! Finance]
Low
Report
PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment [Yahoo! Finance]
3/17
06:32 am
abbv
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer [Yahoo! Finance]
Low
Report
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer [Yahoo! Finance]
3/16
06:36 pm
abbv
1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction [Yahoo! Finance]
Low
Report
1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction [Yahoo! Finance]
3/15
08:00 am
abbv
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Low
Report
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/18
05:00 pm
abbv
Form 4 AbbVie Inc. For: Mar 14 Filed by: Reents Scott T
Low
Report
Form 4 AbbVie Inc. For: Mar 14 Filed by: Reents Scott T
3/14
04:35 pm
abbv
Form 144 AbbVie Inc. Filed by: Reents Scott T
Low
Report
Form 144 AbbVie Inc. Filed by: Reents Scott T
3/10
05:05 pm
abbv
Form PRE 14A AbbVie Inc. For: May 09
Low
Report
Form PRE 14A AbbVie Inc. For: May 09
3/10
04:28 pm
abbv
Form 3 AbbVie Inc. For: Mar 01 Filed by: Purdue David Ryan
Low
Report
Form 3 AbbVie Inc. For: Mar 01 Filed by: Purdue David Ryan
3/4
05:00 pm
abbv
Form 4 AbbVie Inc. For: Feb 28 Filed by: RICHMOND TIMOTHY J.
Low
Report
Form 4 AbbVie Inc. For: Feb 28 Filed by: RICHMOND TIMOTHY J.
3/4
05:00 pm
abbv
Form 4 AbbVie Inc. For: Feb 28 Filed by: Reents Scott T
Low
Report
Form 4 AbbVie Inc. For: Feb 28 Filed by: Reents Scott T
3/4
05:00 pm
abbv
Form 4 AbbVie Inc. For: Feb 28 Filed by: Thakkar Roopal
Low
Report
Form 4 AbbVie Inc. For: Feb 28 Filed by: Thakkar Roopal
3/4
05:00 pm
abbv
Form 4 AbbVie Inc. For: Feb 28 Filed by: Siatis Perry C
Low
Report
Form 4 AbbVie Inc. For: Feb 28 Filed by: Siatis Perry C
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/26
Form PX14A6G AbbVie Inc. Filed by: United Church Funds, Inc.
9.7%
3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%
3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%
2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%
3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%
6/27 AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered [Seeking Alpha] 3.7%
6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%
11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%
8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%
6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%
3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%
3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%
2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%
3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%
6/27 AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered [Seeking Alpha] 3.7%
6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%
11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%
8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%
6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%
TOP News Decliners
6/25
AbbVie nears deal to buy Allergan for more than $60 bln - WSJ [Reuters]
-11.8%
3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%
3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%
2/24 Form 4 AbbVie Inc. For: Feb 20 Filed by: Durkin Brian L -3.9%
10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%
3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%
2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%
3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%
4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%
2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%
3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%
3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%
2/24 Form 4 AbbVie Inc. For: Feb 20 Filed by: Durkin Brian L -3.9%
10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%
3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%
2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%
3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%
4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%
2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: